[Models in the management of long-term life]. / I modelli nella gestione della lungovivenza.

The number of cancer survivors is progressively increasing. Despite the significant progress in the cancer therapies, we are facing the emerging concern of the late side effects and/or psycosocial problems that require diversified follow-up. Healthcare models supporting the oncological patient's needs should be established to improve the quality of life after the diagnosis of oncological disease. Several care models have been proposed - mainly focused on the pediatric population - although further research is needed to optimize the programs. Furthermore, the heterogeneity in existing survivorship care should be addressed: the individual patient characteristics and risk factors (histology, treatment received, age, performance status, comorbidities, lifestyle, behavior risk) should be considered. An efficient cooperation between the General practitioner and the Oncologic team is needed.

Molecular analysis of the APC gene in Sicilian patients with familial adenomatous polyposis (F.A.P.).

Familial adenomatous polyposis (FAP) is an autosomal dominant inherited syndrome, caused by germline mutations in the adenomatous polyposis coli (APC) suppressor gene. Patients with colorectal polyps are more likely to develop a malignant condition with poor prognosis. Typical FAP is characterized by hundreds to thousands of colorectal adenomatous polyps and by several extra-colonic manifestations; an attenuated form of polyposis (AFAP), presenting less than 100 adenomas and later onset, has been reported. In this study we have examined five Sicilian families affected by FAP syndrome, in order to provide predictive genetic testing for the affected families, as well as to contribute to mutation catalog enrichment. We have detected different APC mutations in these five pedigrees, confirming the remarkable heterogeneity of the mutational spectrum in FAP.

Active home-based cancer treatment.

BACKGROUND: Active home-based treatment represents a new model of health care. Chronic treatment requires continuous access to facilities that provide cancer care, with considerable effort, particularly economic, on the part of patients and caregivers. Oral chemotherapy could be limited as a consequence of poor compliance and adherence, especially by elderly patients. METHODS: We selected 30 cancer patients referred to our department and treated with oral therapy (capecitabine, vinorelbine, imatinib, sunitinib, sorafenib, temozolomide, ibandronate). This pilot study of oral therapy in the patient's home was undertaken by a doctor and two nurses with experience in clinical oncology. The instruments used were clinical diaries recording home visits, hospital visits, need for caregiver support, and a questionnaire specially developed by the European Organization for Research and Treatment of Cancer (EORTC), known as the QLQ-C30 version 2.0, concerning the acceptability of oral treatment from the patient's perspective. RESULTS: This program decreased the need to access cancer facilities by 98.1%, promoted better quality of life for patients, as reflected in increased EORTC QLQ-C30 scores over time, allowing for greater adherence to oral treatment as a result of control of drug administration outside the hospital. This model has allowed treatment of patients with difficult access to care (elderly, disabled or otherwise needed caregivers) that in the project represent the majority (78% of these). CONCLUSIONS: This model of active home care improves quality of life and adherence with oral therapy, reduces the need to visit the hospital, and consequently decreases the number of lost hours of work on the part of carers. Management of the service by the professionals involved revealed excellent control of the process by nursing staff, with minimal visits involving doctors.